Corcept Therapeutics Incorporated Stock Market Capitalization
CORT Stock | USD 52.42 2.72 4.93% |
Corcept Therapeutics Incorporated fundamentals help investors to digest information that contributes to Corcept Therapeutics' financial success or failures. It also enables traders to predict the movement of Corcept Stock. The fundamental analysis module provides a way to measure Corcept Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Corcept Therapeutics stock.
Last Reported | Projected for Next Year | ||
Market Cap | 3 B | 3.2 B |
Corcept | Market Capitalization |
Corcept Therapeutics Incorporated Company Market Capitalization Analysis
Corcept Therapeutics' Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Current Corcept Therapeutics Market Capitalization | 5.78 B |
Most of Corcept Therapeutics' fundamental indicators, such as Market Capitalization, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Corcept Therapeutics Incorporated is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Corcept Market Capitalization Driver Correlations
Understanding the fundamental principles of building solid financial models for Corcept Therapeutics is extremely important. It helps to project a fair market value of Corcept Stock properly, considering its historical fundamentals such as Market Capitalization. Since Corcept Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Corcept Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Corcept Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Corcept Market Capitalization Historical Pattern
Today, most investors in Corcept Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Corcept Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's market capitalization growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Corcept Therapeutics market capitalization as a starting point in their analysis.
Corcept Therapeutics Market Capitalization |
Timeline |
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
Competition |
Corcept Long Term Debt To Capitalization
Long Term Debt To Capitalization |
|
Based on the recorded statements, the market capitalization of Corcept Therapeutics Incorporated is about 5.78 B. This is 55.36% lower than that of the Pharmaceuticals sector and 21.86% higher than that of the Health Care industry. The market capitalization for all United States stocks is 69.64% higher than that of the company.
Corcept Market Capitalization Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Corcept Therapeutics' direct or indirect competition against its Market Capitalization to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Corcept Therapeutics could also be used in its relative valuation, which is a method of valuing Corcept Therapeutics by comparing valuation metrics of similar companies.Corcept Therapeutics is currently under evaluation in market capitalization category among its peers.
Corcept Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Corcept Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Corcept Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Corcept Fundamentals
Return On Equity | 0.26 | ||||
Return On Asset | 0.13 | ||||
Profit Margin | 0.23 % | ||||
Operating Margin | 0.26 % | ||||
Current Valuation | 5.4 B | ||||
Shares Outstanding | 104.78 M | ||||
Shares Owned By Insiders | 11.51 % | ||||
Shares Owned By Institutions | 85.40 % | ||||
Number Of Shares Shorted | 17.05 M | ||||
Price To Earning | 30.07 X | ||||
Price To Book | 9.04 X | ||||
Price To Sales | 9.19 X | ||||
Revenue | 482.38 M | ||||
Gross Profit | 396.47 M | ||||
EBITDA | 108.32 M | ||||
Net Income | 106.14 M | ||||
Cash And Equivalents | 370.09 M | ||||
Cash Per Share | 3.45 X | ||||
Total Debt | 151 K | ||||
Debt To Equity | 0.01 % | ||||
Current Ratio | 8.54 X | ||||
Book Value Per Share | 6.10 X | ||||
Cash Flow From Operations | 127.04 M | ||||
Short Ratio | 15.87 X | ||||
Earnings Per Share | 1.26 X | ||||
Price To Earnings To Growth | 0.61 X | ||||
Target Price | 74.9 | ||||
Number Of Employees | 352 | ||||
Beta | 0.46 | ||||
Market Capitalization | 5.78 B | ||||
Total Asset | 621.52 M | ||||
Retained Earnings | 402.53 M | ||||
Working Capital | 354.13 M | ||||
Current Asset | 48.98 M | ||||
Current Liabilities | 20.88 M | ||||
Net Asset | 621.52 M |
About Corcept Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Corcept Therapeutics Incorporated's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Corcept Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Corcept Therapeutics Incorporated based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Corcept Stock Analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.